Liquid Dosage
Insulin
With diabetes on the rise and the global insulin market estimated to be worth more than $32 billion by 2018, demand for GEA technologies for the production of this life-saving drug is already high and set to increase, particularly in new markets and emerging economies.
State-of-the-Art Solutions
GEA produces and supplies process systems for the production of liquid products for the pharmaceutical and biotechnological industries, and has a proven history of successfully installing plant for the production of insulin, including the engineering, delivery, commissioning and qualification of entire ultra-pure media systems as well as various process equipment and cleaning installations.
A worldwide technology leader in insulin production, GEA is able to supply the clean utility systems and manage the integration of all the main processes, including fermentation, harvesting, chromatography, filtration and freeze drying.
From Fermentation to Freeze Drying
The biosynthetic production of human insulin is done using bacteria or yeast cells. Following fermentation, or the conversion of chemical raw materials by micro-organisms, the biomass is extracted using a nozzle separator, washed, concentrated and finally precipitated to produce insulin crystals.
Centrifuges and process lines provided by GEA have an established pedigree in the clarification, separation, classification, concentration and fractionation steps. Nozzle separators also play an important part in the production process. Further, GEA chamber or self-cleaning separators can be used in the subsequent crystallization stages.
GEA is a single-source supplier of a variety of fermenters, media preparation, buffer storage, harvesting and cell rupture solutions, equipment for the purification and isolation of cells, separation (after both first and final crystallization), the production and distribution of WFI, CIP and freeze drying technologies, all of which can be installed and integrated into a state-of-the-art insulin production facility.
Prodotti e tecnologie
Visualizzazione di 4 su 14
Blocco di compressione omogeneizzatore
Le testate di compressione di GEA sono il cuore pulsante dell'omogeneizzatore poiché attivano il processo di omogeneizzazione pompando il prodotto ad alta pressione per convogliarlo all'interno della valvola di omogeneizzazione.
Lyophilizers (Pharma Freeze Dryers)
GEA's thorough understanding of the lyophilization process enables them to supply a comprehensive range of products and services, comprising laboratory equipment, pilot plants for research and small-scale production batches, industrial size pharmaceutical production freeze dryers.
Omogeneizzatori da laboratorio
Gli omogeneizzatori da laboratorio GEA, piccoli e compatti, consentono di testare gli effetti dell'omogeneizzazione sul prodotto e valutare quali sono i migliori parametri di processo.
Omogeneizzatori industriali
Gli omogeneizzatori industriali GEA sono costituiti da due elementi essenziali: un blocco di compressione che consente di pompare il prodotto ad alta pressione e una valvola di omogeneizzazione, in grado di micronizzare le particelle disperse fino a un ordine di grandezza micrometrica e nanometrica, a seconda delle caratteristiche del prodotto e ...
Downloads
Approfondimenti GEA
Kytero 10 I grandi cambiamenti iniziano in piccolo
Con GEA kytero 10, i ricercatori e gli sviluppatori dei settori biofarmaceutico, alimentare e New Food hanno ora a disposizione un potente acceleratore di ultima generazione.
Fueling the circular economy in shipping
Ports now compete not just on logistics, but on sustainability. At Greece’s Piraeus port, an advanced processing and recovery facility recycles ship waste oil into fuel. Equipped with GEA’s high-performance centrifuges, it sets a new benchmark for state-of-the-art, environmentally responsible port operations.
Uova più sostenibili sulle nostre tavole
GEA aiuta i clienti a testare e sviluppare prodotti e ingredienti alternativi alle uova realizzati con la fermentazione di precisione.
